Gates Package — page 257

Members of the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) Partnership Novavax, Inc. Emmanuel Hanon, Ph.D. Senior Vice President of Vaccines Research and Development GlaxoSmithKline Barton Haynes, M.D. Frederic M. Hanes Distinguished Professor of Medicine Director, Duke Human Vaccine Institute Duke University Peter Hotez, M.D., Ph.D. Dean, National School of Tropical Medicine, Baylor College of Medicine; Director, Center for Vaccine Development, Texas Children's Hospital Kathrin Jansen, Ph.D. (Co-Chair) Senior Vice President and Head of Vaccine Research and Development Pfizer Antonio Lanzavecchia, M.D. Senior Vice President and Senior Research Fellow, Vir Biotechnology, Inc.; Director, Institute for Research in Biomedicine Douglas Lowy, M.D. (Co-Chair) Principal Deputy Director National Cancer Institute, NIH Peter Marks, M.D., Ph.D. Director, Center for Biologics Evaluation and Research U.S. Food and Drug Administration John Mascola, M.D. Director, Dale and Betty Bumpers Vaccine Research Center National Institute of Allergy and Infectious Diseases, NIH Nancy Messonnier, M.D. Director, Center for the National Center for Immunization and Respiratory Diseases Centers for Disease Control and Prevention Nelson Michael, M.D., Ph.D. Director, Center for Infectious Diseases Research Walter Reed Army Institute of Research, U.S. Army Medical Research and Development Command Paul Offit, M.D. Director, Vaccine Education Center Maurice R. Hilleman Professor of Vaccinology, Perelman School of Medicine, University of Pennsylvania; Professor, Children's Hospital of Philadelphia